Clinical Scorecard: Developing and Validating a Clinical Prediction Model for Early Identification of Heart Failure Risk in Asymptomatic Patients with Type 2 Diabetes

At a Glance

Key Highlights

• Developed a clinical prediction model for heart failure risk in asymptomatic T2DM patients.
• Identified independent predictors including LASr, NT-proBNP, and galectin-3.
• Stratified patients into low, intermediate, and high-risk groups based on a scoring system.
• Achieved a C-statistic of 0.835 for the prediction model.
• SGLT2i/GLP-1 RA use associated with lower observed risk.

Guideline-Based Recommendations

Diagnosis

• Use echocardiographic assessments to evaluate cardiac function in asymptomatic T2DM patients.

Management

• Consider integrating LASr and galectin-3 in risk assessment for heart failure.

Monitoring & Follow-up

• Regular follow-up assessments for cardiac function in asymptomatic T2DM patients.

Risks

• Monitor for progression to heart failure in patients with identified risk factors.

Patient & Prescribing Data

Asymptomatic T2DM patients with preserved LVEF.

SGLT2i and GLP-1 RA may reduce heart failure risk.

Clinical Best Practices

• Utilize a multi-faceted approach including clinical variables and biomarkers for risk stratification.
• Implement regular echocardiographic evaluations to monitor cardiac health.

Related Resources & Content

• IDF Diabetes Atlas 2024
• Meta-analysis on T2DM and HF risk
• Diabetic cardiomyopathy review